跳转至内容
Merck

[Clofibrate treatment of hyperlipoproteinemia].

Nihon rinsho. Japanese journal of clinical medicine (1994-12-01)
S Oikawa, H Midorikawa
摘要

Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL decreases. Therefore Clofibrate decreases not only plasma triglyceride but cholesterol levels. It has been reported that Clofibrate have a preventive effect on cardiovascular disease. So these agents are useful in the treatment for hyperlipidemic patients with or without atherosclerosis.

材料
货号
品牌
产品描述

Sigma-Aldrich
氯贝丁酯, liquid
Supelco
氯贝丁酯, analytical standard
氯贝丁酯, European Pharmacopoeia (EP) Reference Standard